1K9 Stock Chart & Stats
€43.00
€0.00(0.00%)
At close: 4:00 PM EDT
€43.00
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€12.16 - €63.50
Previous CloseN/A
Volume0.00
Average Volume (3M)45.00
Market Cap
€3.20B
Enterprise Value€1.17B
Total Cash (Recent Filing)€373.64M
Total Debt (Recent Filing)€19.25M
Price to Earnings (P/E)32.2
Beta0.49
Next Earnings
Oct 29, 2026EPS Estimate
0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.15
Shares Outstanding51,734,222
10 Day Avg. Volume23
30 Day Avg. Volume45
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)3.31
Price to Sales (P/S)2.64
P/FCF Ratio27.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€50.75Price Target Upside18.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)1.07
Revenue Forecast (FY)€440.83M
Bulls Say, Bears Say
Bulls Say
Medicare CoverageThe finalized Medicare determination reduces reimbursement uncertainty for core surveillance tests and creates a framework for expanding coverage. More predictable payment support can encourage transplant-center adoption, strengthen recurring test utilization, and improve the commercial potential of future products.
Balance Sheet StrengthA debt-free balance sheet and substantial cash reserve provide financial flexibility to fund clinical programs, commercial expansion, and NavDx integration without relying heavily on external financing. This capitalization also improves resilience if operating performance temporarily softens.
Clinical DifferentiationEvidence that CareDx monitoring can reduce invasive biopsies while retaining predictive performance under updated pathology standards supports clinical utility. Stronger evidence can reinforce physician adoption, differentiate the platform, and broaden the role of molecular surveillance in transplant care.
Bears Say
Earnings VolatilityRecent profitability is encouraging, but repeated losses across prior periods indicate that earnings durability has not yet been fully demonstrated. A return of weaker volumes, reimbursement pressure, or higher spending could therefore produce greater profit volatility than current results imply.
High Operating ExpensesThe elevated operating expense base limits how much revenue growth converts into durable operating profit. Maintaining margins will require CareDx to scale testing and new offerings efficiently; otherwise, continued investment could constrain cash generation and reduce earnings leverage.
NavDx Margin And Integration RiskNavDx expands CareDx into a new diagnostic opportunity but currently carries lower average selling prices and margins than the transplant testing business. Integration across billing, claims, and workflows must succeed for the acquisition to improve earnings rather than dilute margins.
CareDx News
1K9 FAQ
What was CareDx’s price range in the past 12 months?
CareDx lowest stock price was €12.16 and its highest was €63.50 in the past 12 months.
What is CareDx’s market cap?
CareDx’s market cap is €3.20B.
When is CareDx’s upcoming earnings report date?
CareDx’s upcoming earnings report date is Oct 29, 2026 which is in 3 days.
How were CareDx’s earnings last quarter?
CareDx released its earnings results on Jul 30, 2026. The company reported €0.33 earnings per share for the quarter, beating the consensus estimate of €0.207 by €0.123.
Is CareDx overvalued?
According to Wall Street analysts CareDx’s price is currently Undervalued.
Does CareDx pay dividends?
CareDx does not currently pay dividends.
What is CareDx’s EPS estimate?
CareDx’s EPS estimate is 0.23.
How many shares outstanding does CareDx have?
CareDx has 51,734,222 shares outstanding.
What happened to CareDx’s price movement after its last earnings report?
CareDx reported an EPS of €0.33 in its last earnings report, beating expectations of €0.207. Following the earnings report the stock price went up 16.993%.
Which hedge fund is a major shareholder of CareDx?
Currently, no hedge funds are holding shares in DE:1K9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CareDx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€50.75 (18.02% Upside)
€50.75 (18.02% Upside)
Blogger Sentiment
Neutral
DE:1K9 Sentiment 78%
Sector Average 67%
Sector Average 67%
Insider Transactions
Sold Shares
Worth €3.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
370.81%
12-Months-Change
Fundamentals
Return on Equity
32.81%
Trailing 12-Months
Asset Growth
19.97%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
CareDx
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
1K9 Company Deck
1K9 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong organic and inorganic growth, material margin expansion, a fortified balance sheet, and substantive clinical and reimbursement milestones (Medicare LCD, KOAR data, AlloHeme and HistoMap publications). Key near-term risks include sizable operating expense run-rate, material out-of-period revenue that inflated reported margins this quarter, and execution/integration risk around the NavDx acquisition and specialty oncology ASP/margin improvement. Management raised 2026 guidance while taking a conservative approach to NavDx assumptions and flagged potential modest near-term investments that could temper margin expansion. Overall, the positives around revenue growth, cash position, clinical evidence, and coverage developments outweigh the operational and integration cautions.View all DE:1K9 earnings summaries1K9 Stock 12 Month Forecast
Average Price Target
€50.75
▲(18.02% Upside)